Table 1 Arterial problems in patients treated with TKIs
Reference Study design | N | Treatment | Follow-up | Cardiovascular event | IHD | ICVE | PAOD | Other | Median time to event (range) |
|---|---|---|---|---|---|---|---|---|---|
Aichberger et al.53 retrospective cohort analysis (single centre) | 24 | Nilotinib | 24 months | 6 (25%) | 1 (4%) | NR | 4 (16.7%) | 1 (4%) | 11 (10–39) months |
Tefferi et al.38 case report | 2 | Nilotinib | NR | NR | NR | NR | 2 | NR | NR |
le Coutre et al.39 retrospective cohort analysis (multicentric) | 179 | Nilotinib | NR | NR | NR | NR | 11 (6.2%) | NR | 26 (4–53) months |
Quintas-Cardama et al.40 retrospective cohort analysis (single centre) | 233 | Nilotinib | NR | NR | NR | 1 (0.4%) | 3 (1.3%) | 1 (0.4%) | NR |
Labussiere-Wallet et al.41 prospective cohort screening (single centre) | 54 | Nilotinib | NR | NR | 1 (1.9%) | 2 (3.7%) | 4 (7.4%) | NR | 31 (7–53) months |
Giles et al.32 retrospective cohort analysis (multicentric, pooled trials) | 556 | Nilotinib | NR | NR | NR | NR | 7 (1.2%) | NR | NR |
1301 | Imatinib | NR | NR | NR | NR | 2 (0.2%) | NR | NR | |
533 | Interferon | NR | NR | NR | NR | 3 (0.6%) | NR | NR | |
Kim et al.33 retrospective cohort analysis (multicentric)/prospective cohort screening (single centre) | 66 | Nilotinib | NR | NR | NR | NR | 7 (10.6%) | NR | 40 (21–56) months |
54 | Imatinib | NR | NR | NR | NR | 1 (1.9%) | NR | NR | |
Levato et al.42 retrospective cohort analysis (single centre) | 27 | Nilotinib | NR | NR | 1 (3.7%) | 1 (3.7%) | 2 (7.4%) | NR | 24 (7–34) months |
Giles et al. (ENEST1st)43 prospective phase IIIb (multicentric) | 819 | Nilotinib | NR | NR | 31 (3.8%) | 4 (0.5%) | 13 (1.6%) | NR | NR |
Jeon et al.44 prospective cohort screening (single centre) | 88 | Nilotinib | NR | NR | NR | NR | 3 (3.4%) | NR | NR |
le Coutre et al.45 retrospective cohort analysis (multicentric, pooled trials) | 2705 | Dasatinib | NR | NR | NR | NR | 6 (0.2%) | NR | 20 (2–53) months |
Cortes et al. (PACE)23 prospective phase II (multicentric) | 449 | Ponatinib | 3 years | 99 (22%) | 52 (12%) | 37 (8%) | 37 (8%) | NR | NR |
Larson et al. (ENESTnd)46 prospective phase III (multicentric) | 279 | Nilotinib 300 mg BID | 72 months | 28 (10%) | 14 (5%) | 4 (1.4%) | 12 (4.3%) | 4 (1.4%) | 30 (6–78) months |
277 | Nilotinib 400 mg BID | 44 (15.9%) | 18 (10.1%) | 9 (3.2%) | 9 (3.2%) | 3 (1.1%) | 36 (6–90) months | ||
280 | Imatinib 400 mg QD | 7 (2.5%) | 6 (2.1%) | 1 (0.4%) | 0 | 0 | 42 (6–78) months | ||
Gugliotta et al. (GIMEMA)47 prospective phase II (multicentric) | 215 | Nilotinib | 57 months | 13 (6%) | 3 (1.4%) | NR | 4 (1.9%) | NR | 37 months |
Gora-Tybor et al.54 retrospective cohort analysis (multicentric) | 50 | Dasatinib | 28 months | 2 (4%) | 1 (2%) | 1 (2%) | 0 | 0 | 20 (19–22) months |
55 | Nilotinib | 6 (11%) | 2 (3.6%) | 1 (1.8%) | 1 (1.8%) | 2 (3.6%) | 15 (6–69) months | ||
Hadzijusufovic et al.48 retrospective cohort analysis (single centre) | 36 | Nilotinib | 44 months | NR | NR | NR | 16 (44.4%) | NR | NR |
Fossard et al.49 prospective cohort analysis (multicentric) | 114 | Nilotinib | NR | 21 (18.5%) | NR | NR | NR | NR | 47 (8–82) months |
Gilbert et al.50 retrospective cohort analysis (single centre) | 183 | Nilotinib | NR | 20 (10.9%) | 9 (5%) | 4 (2%) | 7 (4%) | NR | NR |
Rea et al.51 retrospective cohort analysis (single centre) | 57 | Nilotinib | 47 months | 13 (23%) | 3 (5%) | 2 (4%) | 8 (14%) | NR | 28 (9–50) months |
Cortes et al. (DASISION)52 prospective phase III (multicentric) | 259 | Dasatinib | 60 months | 12 (5%) | 10 (3.9%) | 2 (0.7%) | 0 | NR | NR |
Hochhaus et al.36 prospective cohort analysis (multicentric) | 1089 | Nilotinib 600 | 24 months | 65 (6%) | 37 (3.4%) | 9 (0.8%) | 21 (1.9%) | NR | NR |
Hochhaus et al.37 prospective cohort analysis (multicentric) | 279 | Nilotinib 600 | 60 months | 21 (7.5%) | 11 (3.9%) | 4 (1.4%) | 7 (2.5%) | NR | NR |
Hochhaus et al.37 prospective cohort analysis (multicentric) | 277 | Nilotinib 800 | 60 months | 37 (13.4%) | 24 (8.7%) | 9 (3.2%) | 7 (2.5%) | NR | NR |
Hochhaus et al.37 prospective cohort analysis (multicentric) | 280 | Imatinib 400 | 60 months | 6 (2.1%) | 5 (1.8%) | 1 (0.4%) | 0 | NR | NR |
